Fieldview Capital Management LLC Makes New Investment in DexCom, Inc. $DXCM

Fieldview Capital Management LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,822 shares of the medical device company’s stock, valued at approximately $453,000.

Other large investors have also modified their holdings of the company. CVA Family Office LLC raised its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the period. MCF Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth about $32,000. ORG Partners LLC raised its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the last quarter. Spire Wealth Management raised its position in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the last quarter. Finally, Aventura Private Wealth LLC acquired a new position in shares of DexCom during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In related news, EVP Jon Coleman sold 4,911 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares of the company’s stock, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 40,994 shares of company stock worth $2,919,022 in the last 90 days. 0.28% of the stock is currently owned by insiders.

DexCom Stock Down 1.5%

Shares of NASDAQ DXCM opened at $74.22 on Tuesday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The stock has a market cap of $28.64 billion, a PE ratio of 31.72, a P/E/G ratio of 1.18 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a 50-day moving average of $66.37 and a 200 day moving average of $67.68.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter in the prior year, the company earned $0.32 EPS. DexCom’s revenue was up 15.0% compared to the same quarter last year. As a group, sell-side analysts predict that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

DXCM has been the subject of several research analyst reports. Raymond James Financial restated a “strong-buy” rating and set a $91.00 price target on shares of DexCom in a research report on Monday, June 8th. Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Finally, Stifel Nicolaus set a $90.00 price objective on DexCom and gave the company a “buy” rating in a research note on Friday, June 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $84.83.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.